Key facts
- Citizens reiterates stock rating on Kura Oncology.
- Rating based on FIT-001 data.
- Kura Oncology previously announced phase 1a data for a cancer drug combination.
Citizens has reiterated its stock rating on Kura Oncology. The decision to maintain the rating is based on data released from FIT-001. This news follows Kura Oncology's earlier announcement regarding phase 1a data for a cancer drug combination therapy. The combination therapy involves two drugs, tipifarnib and MEK162, and represents an ongoing effort in cancer treatment research by the company.